Dr. Sherri McFarland, PhD
Professor, Department of Chemistry (Acadia)
Adjunct Professor, School of Biomedical Engineering and Pathology (Dalhousie)
inorganic photophysics, photosensitizers, photodynamic therapy, phototherapy, photomedicine, medicinal chemistry, drug design,chemical biology
We combine light and molecules to act as therapeutic and diagnostic agents in anticancer therapy.
The McFarland group is multidisciplinary, with projects aimed at designing novel metallodrug photosensitizers as agents for photodynamic therapy (PDT). Our interest in photomedicine, particularly in the development of theranostic agents, has taken us from just ideas on paper –the use of ruthenium and osmium-based complexes to overcome the inherent limitations of organic photosensitizers– to a Phase 1 human clinical trial in 2015 for treating bladder cancer with PDT using one of our photosensitizers. We are now focused on using similar strategies for developing PDT for melanoma.
Membership Status:Dr. Sherri McFarland is a Senior Scientist
Address:Department of Chemistry, Acadia University, 6 University Ave., Elliott Hall Rm. 217, Wolfville, NS B4P 2R6
Ru(II) Dyads Derived from α-Oligothiophenes: a New Class of Potent and Versatile Photosensitizers for PDT: Coord. Chem. Rev., 2015, 282-283, 127-138. DOI 10.1016/j.ccr.2014.04.012
Ru(II) Dyads Derived from 2-(1-Pyrenyl)-1H-imidazo[4,5-f][1,10]phenanthroline: Versatile Photosensitizers for Photodynamic Applications: J. Phys. Chem. A, 2014, 118, 10507-10521. DOI:10.1021/jp504330s
In Vitro Multiwavelength PDT with 3IL States: Teaching Old Molecules New Tricks: Inorg. Chem., 2014, 53, 4548−4559. DOI 10.1021/ic5002368